您要查找的是不是：
- Pharmacophore hypothesis(PH) is fundamental to de novo design of peptide ligand based on the structure of target protein. 在基于靶蛋白結構的多肽分子設計中，藥效假說(shuō)是從頭設計方法的基本前提。
- De Novo Design and Synthesis of Nonpeptidic Inhibitors Based on the Structure of HIV-1 Protease 基于HIV-1蛋白酶結構的非肽抑制劑的全新分子設計與合成
- And such an inhibition might necessitate de novo protein synthesis. 而這種抑制作用需要新的蛋白質(zhì)合成。
- The de novo synthesis of PC increases in PE-SWD. 以同位素示蹤法測得海水淹溺后肺組織初始原料合成(de novo)的TPL和DSPC增加。
- The de novo protein synthesis of coccoid form was even higher than those of spiral form. 相反的，而在球形體新合成的蛋白質(zhì)則明顯高于桿狀體。
- Basic theory, procedure and applications of de novo drug design are introduced, and the strategies for leads generation are emphasized at length. 全新藥物設計方法是一種基于受體結構三維信息,采用計算機輔助藥物設計技術(shù),設計出能與受體特異性結合的先導化合物。
- De novo sequencing provides proteomics research work a new method to interpret tandem mass spectrum data without any help of protein sequence databases. 從頭測序為蛋白質(zhì)組研究提供了一種不用借助于任何蛋白質(zhì)序列數據庫信息,直接解讀串聯(lián)質(zhì)譜數據的方法。
- The mutation,G2043R is cause of patient with DEB.It is a mutation of de novo. COL7A1基因的G2043R突變可能是引起本例臨床表現的原因,且是一個(gè)denovo突變。
- The de novo synthesis of dioxins formation is introduced in this article. 介紹了二惡英的從頭合成機理。
- De novo drug design is a structure based durg design method, which employs computational methods to generate and optimize leads, based on three dimensional receptor structural information. 簡(jiǎn)要概述全新藥物設計方法的一般原理、步驟及應用實(shí)例,重點(diǎn)評述全新藥物設計方法中分子生成策略的進(jìn)展。
- The detailed docking for de novo ligand design and the rough docking for known chemical database screening for drug discovery. Their demands for the global minimization algorithms are different. 對接可分為兩類(lèi):主要用于從頭配體設計的細致對接和用于已知化合物數據庫篩選以發(fā)現藥物的粗略對接;它們對全局極小化算法的要求是不同的.
- The experiments showed that KT promoted SOD de novo biosynthesis mainly on the transciriptional level. 試驗表明，激動(dòng)素主要是在轉錄水平上促進(jìn)SOD的從頭合成。
- The 12-month all-cause mortality was 27.4%, and was higher among those with decompensated congestive HF (33.5%) than the de novo HF group. 12個(gè)月的全因死亡率為27.;4%25，并且失代償性充血性心力衰竭組（33
- Should this be found to be true after re-examination, the people's court shall conduct a trial de novo. 經(jīng)人民法院審查屬實(shí)的，應當再審。
- The other component includes metachronous tumors that arise de novo in a preneoplastic cirrhotic liver. 其他成分，包括在腫瘤（發(fā)生）前的硬變肝內出現新形成的異時(shí)腫瘤。
- The psoriasis with leukemia was similar to de novo leukemia in its clinical feature and results of laboratory test. 銀屑病患白血病者的臨床表現、治療效果及染色體結果與原發(fā)性白血病改變相類(lèi)似。
- Evi-1 expression was positive in 6 Of 9 post-MDS AML while only in 5 of 34 de novo AML patients (p<0.01). Evi-1和MDS1-Evi-1表達陽(yáng)性的MDS病例沒(méi)有發(fā)現3號染色體異常，但8例7號染色體異常(-7)的患者中，7例Evi-1表達陽(yáng)性。
- MDS1-Evi-1 expression was found in 6 of 9 post-MDS AML and 8 of 34 de novo AML patients (p<0.05). Evi-1或MDS1-Evi-1表達陽(yáng)性和陰性MDS病例之間骨髓細胞凋亡相關(guān)參數沒(méi)有明顯差異。 這兩個(gè)基因表達陽(yáng)性患者的CFU-GM，CFU-E和BFU-E平均產(chǎn)率較各自表達陰性者有不同程度的減少。
- A case from the same era called for de novo review of whether a ratesetting order was confiscatory. 同一年代的一個(gè)案件要求重新審查某一確定價(jià)格的命令是否應當收日。
